BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22837027)

  • 1. Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next?
    Harenberg J; Marx S; Wehling M
    Thromb Haemost; 2012 Sep; 108(3):407-9. PubMed ID: 22837027
    [No Abstract]   [Full Text] [Related]  

  • 2. Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation.
    Skjøth F; Larsen TB; Rasmussen LH
    Thromb Haemost; 2012 Sep; 108(3):405-6. PubMed ID: 22782445
    [No Abstract]   [Full Text] [Related]  

  • 3. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New oral anticoagulant in atrial fibrillation: are they comparable?
    Kalodiki E; Lewis B; Fareed J
    Int Angiol; 2012 Aug; 31(4):307-9. PubMed ID: 22801395
    [No Abstract]   [Full Text] [Related]  

  • 5. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
    Ahrens I; Lip GY; Peter K
    Thromb Haemost; 2011 Apr; 105(4):574-8. PubMed ID: 21225102
    [No Abstract]   [Full Text] [Related]  

  • 6. [New anticoagulants in patients with atrial fibrillation].
    Diener HC; Weber R
    MMW Fortschr Med; 2013 May; 155(8):55-6, 58. PubMed ID: 24437140
    [No Abstract]   [Full Text] [Related]  

  • 7. [Stroke risk--atrial fibrillation].
    Dabitz R; Ochs G
    MMW Fortschr Med; 2012 Nov; 154(19):53-6. PubMed ID: 23173288
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
    Ezekowitz MD; Kent AP
    Circulation; 2014 Oct; 130(17):1505-14. PubMed ID: 25332278
    [No Abstract]   [Full Text] [Related]  

  • 10. [Structured care for patients with new oral anticoagulants. Nursing based care of adults with atrial fibrillation].
    Al-Khalili F; Lindström C
    Lakartidningen; 2014 Oct 1-7; 111(40):1720-2. PubMed ID: 25759883
    [No Abstract]   [Full Text] [Related]  

  • 11. Defining non-valvular atrial fibrillation while selecting anticoagulation therapy.
    Garg P; Ripley DP
    Br J Hosp Med (Lond); 2015 Feb; 76(2):66-7. PubMed ID: 25671468
    [No Abstract]   [Full Text] [Related]  

  • 12. [Differential therapy with the new anticoagulants, 5].
    Stiefelhagen P
    MMW Fortschr Med; 2013 May; 155(9):20. PubMed ID: 23951642
    [No Abstract]   [Full Text] [Related]  

  • 13. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
    Bauer KA
    Stroke; 2013 Jun; 44(6 Suppl 1):S38-40. PubMed ID: 23709725
    [No Abstract]   [Full Text] [Related]  

  • 14. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
    Lane DA; Wood K
    Circulation; 2015 Apr; 131(16):e412-5. PubMed ID: 25901074
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New oral anticoagulants in the management of venous thromboembolism: a major advance?
    Sciascia S; Hunt BJ
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):487-8. PubMed ID: 25150440
    [No Abstract]   [Full Text] [Related]  

  • 18. ["Xa-tra-xa": opportunities and open questions about new anticoagulants].
    Beer JH
    Praxis (Bern 1994); 2011 Aug; 100(16):947. PubMed ID: 21910293
    [No Abstract]   [Full Text] [Related]  

  • 19. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New agents to prevent strokes in nonvalvular atrial fibrillation.
    Putney D; Pratt C
    Methodist Debakey Cardiovasc J; 2012; 8(3):44-6. PubMed ID: 23227289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.